

Overall Report

Round 14 of
Blood coagulation + coagulation factors
External Quality Assessment

Vienna, 20.05.2021

Dear Colleague,

The distribution of samples for round 14 of the external quality assessment scheme Blood coagulation + coagulation factors was started on 26.04.2021. The return deadline was 15.05.2021. Statistical analysis and evaluation of results were performed on 20.05.2021.

The following samples were circulated:

Sample option	Name	Manufacturer
A	Kontrollplasma P	Siemens
B	Kontrollplasma N	Siemens

Explanatory notes on the table columns

Sample	respective sample
AnzE	number of reported results

Metric results

Collective	collective of methods to which your results were assigned
*	collective not evaluated (either because the number of results in the collective is less than 6 or the number of results within the acceptance limits is less than 5); results are given for informative purposes only
Target value	target value assigned to the sample in this round [method used to determine the target value]:
	[a] Reference value
	[b] Consensus value
%-Dev	acceptable deviation from target value in %
ALimits	acceptance interval
Inside	number and proportion of results that lie within the acceptance interval
Outside	number and proportion of results that lie outside the acceptance interval
MV	mean
Median	median
SD	Standard deviation
CV	coefficient of variation

Nominal results

Result	results reported by participants
Reference	the result(s) assigned to the sample in the respective round [method used to determine the reference]:
	[a] Reference value
	[b] Consensus value
Proportion	Number and proportion of results that correspond to the reference(s)

The following results were obtained:



Thromboplastin time (quick) %

Split: Methode


Collective	Sample	AnzE	Target	%-Abw	limits	correct	outliers	MW	Median	SD	CV %
all	A	245	37.9 [b]	20	[30.3...45.5]	223 (91%)	22 (9%)	37.9	38.0	4.1	10.92
	B	246	93.1 [b]	20	[74.5...111.7]	232 (94%)	14 (6%)	93.1	94.0	6.5	6.97
Cube-S/*****	A	1	46.6 [b]*	20*	[37.3...55.9]*	1 (100%)*	0 (0%)*	46.6*	46.6*	.*	.*
	B	1	115.8 [b]*	20*	[92.6...139.0]*	1 (100%)*	0 (0%)*	115.8*	115.8*	.*	.*
Innovin-Multi-Kal./recomb.	A	31	33.8 [b]	20	[27.0...40.6]	31 (100%)	0 (0%)	33.8	34.0	1.5	4.48
	B	31	91.9 [b]	20	[73.6...110.3]	31 (100%)	0 (0%)	91.9	93.0	3.2	3.43
Innovin/recomb.	A	13	35.0 [b]	20	[28.0...41.9]	11 (85%)	2 (15%)	35.0	35.0	1.6	4.70
	B	13	93.3 [b]	20	[74.6...112.0]	11 (85%)	2 (15%)	93.3	92.8	5.1	5.45
Neoplastine	A	10	38.4 [b]	20	[30.7...46.1]	10 (100%)	0 (0%)	38.4	38.0	2.3	6.11
	B	10	93.0 [b]	20	[74.4...111.6]	10 (100%)	0 (0%)	93.0	92.0	7.2	7.75
PT Rec/human	A	7	32.1 [b]	20	[25.7...38.5]	7 (100%)	0 (0%)	32.1	32.2	1.6	5.11
	B	7	95.3 [b]	20	[76.2...114.4]	7 (100%)	0 (0%)	95.3	96.3	3.3	3.43
PT Screen/human	A	25	42.9 [b]	20	[34.4...51.5]	24 (96%)	1 (4%)	42.9	42.6	2.9	6.75
	B	25	88.7 [b]	20	[70.9...106.4]	25 (100%)	0 (0%)	88.7	88.2	7.0	7.90
PT-Dimex jr./bovine+	A	2	62.5 [b]*	20*	[50.0...75.0]*	2 (100%)*	0 (0%)*	62.5*	62.5*	12.2*	19.53*
	B	2	99.0 [b]*	20*	[79.2...118.8]*	2 (100%)*	0 (0%)*	99.0*	99.0*	35.5*	35.86*
ReadiPlasTin/recomb.	A	26	38.9 [b]	20	[31.1...46.7]	26 (100%)	0 (0%)	38.9	39.0	1.6	4.08
	B	26	98.1 [b]	20	[78.5...117.7]	26 (100%)	0 (0%)	98.1	99.0	3.2	3.26
RecombiPlasTin 2G/recomb.	A	16	37.9 [b]	20	[30.3...45.4]	15 (94%)	1 (6%)	37.9	38.0	2.5	6.65
	B	16	96.4 [b]	20	[77.1...115.7]	15 (94%)	1 (6%)	96.4	95.6	5.8	6.04
STA HEPATO-PREST	A	9	33.4 [b]	20	[26.7...40.1]	9 (100%)	0 (0%)	33.4	33.0	2.1	6.24
	B	9	91.9 [b]	20	[73.5...110.2]	9 (100%)	0 (0%)	91.9	93.0	10.4	11.34
STA-NeoPTimal/rabbit	A	28	37.5 [b]	20	[30.0...45.1]	28 (100%)	0 (0%)	37.5	37.6	1.4	3.61
	B	28	96.0 [b]	20	[76.8...115.2]	28 (100%)	0 (0%)	96.0	95.5	3.1	3.21
Smart 700/*****	A	1	70.6 [b]*	20*	[56.5...84.7]*	1 (100%)*	0 (0%)*	70.6*	70.6*	.*	.*
	B	1	140.0 [b]*	20*	[112.0...150.0]*	1 (100%)*	0 (0%)*	140.0*	140.0*	.*	.*

Smart 700/340/*****	B	1	130.1 [b]*	20*	[104.1...150.0]*	1 (100%)*	0 (0%)*	130.1*	130.1*	.*	.*
Technoclot PT Owren	A	13	38.5 [b]	20	[30.8...46.2]	11 (85%)	2 (15%)	38.5	38.0	7.0	18.31
	B	13	84.0 [b]	20	[67.2...100.8]	11 (85%)	2 (15%)	84.0	81.2	12.6	15.06
Thromborel S	A	63	39.3 [b]	20	[31.5...47.2]	60 (95%)	3 (5%)	39.3	39.5	3.9	9.82
	B	63	91.5 [b]	20	[73.2...109.9]	58 (92%)	5 (8%)	91.5	91.6	7.7	8.44

S-Curves of all samples



Youden-Plots of all sample pairs





- Cube-S/*****
- ◆ Neoplastine
- ▼ ReadiPlasTin/recomb.
- STA-NeoPTimal/rabbit
- ◆ Thromborel S
- Innovin-Multi-Kal./recomb.
- ▲ PT Rec/human
- ◆ RecombiPlasTin 2G/recomb.
- ▲ *alle*
- PT Screen/human
- PT-Dimex jr./bovine+
- Smart 700/*****
- ▼ Technoclot PT Owren
- ▼ Innovin/recomb.
- ▲ STA HEPATO-PREST

INR


Split: Methode

Collective	Sample	AnzE	Target	%-Abw	limits	correct	outliers	MW	Median	SD	CV %
all	A	249	1.92 [b]	20	[1.53...2.30]	237 (95%)	12 (5%)	1.92	1.90	0.16	8.59
	B	247	1.05 [b]	20	[0.84...1.26]	239 (97%)	8 (3%)	1.05	1.04	0.05	5.00
bovine	A	6	1.45 [b]	20	[1.16...1.74]	6 (100%)	0 (0%)	1.45	1.39	0.17	11.48
	B	6	0.88 [b]	20	[0.71...1.06]	5 (83%)	1 (17%)	0.88	0.87	0.11	12.47
human	A	97	1.90 [b]	20	[1.52...2.28]	94 (97%)	3 (3%)	1.90	1.91	0.16	8.37
	B	96	1.07 [b]	20	[0.86...1.29]	93 (97%)	3 (3%)	1.07	1.07	0.07	6.36
rabbit	A	57	1.99 [b]	20	[1.59...2.39]	54 (95%)	3 (5%)	1.99	2.05	0.18	8.91
	B	57	1.04 [b]	20	[0.83...1.25]	57 (100%)	0 (0%)	1.04	1.04	0.04	3.87
recombinant	A	89	1.89 [b]	20	[1.51...2.27]	86 (97%)	3 (3%)	1.89	1.88	0.08	4.44
	B	88	1.03 [b]	20	[0.82...1.23]	85 (97%)	3 (3%)	1.03	1.03	0.04	3.58

S-Curves of all samples



Youden-Plots of all sample pairs




Partielle Thromboplastinzeit (aPTT) sec


Split: Methode

Collective	Sample	AnzE	Target	%-Abw	limits	correct	outliers	MW	Median	SD	CV %
all	A	222	63 [b]	20	[51...76]	96 (43%)	126 (57%)	63	56	15	23.22
	B	223	29 [b]	20	[23...34]	213 (96%)	10 (4%)	29	29	3	12.25
Actin FS	A	54	48 [b]	20	[38...57]	52 (96%)	2 (4%)	48	46	4	8.19
	B	55	24 [b]	20	[20...29]	54 (98%)	1 (2%)	24	24	1	3.84
Actin andere	A	13	71 [b]	20	[57...85]	13 (100%)	0 (0%)	71	71	5	7.41
	B	13	24 [b]	20	[19...29]	12 (92%)	1 (8%)	24	24	1	3.54
Dapttin	A	3	82 [b]*	20*	[66...99]*	3 (100%)*	0 (0%)*	82*	76*	15*	18.14*
	B	3	29 [b]*	20*	[23...35]*	3 (100%)*	0 (0%)*	29*	29*	0*	0.00*
Pathromtin SL	A	35	91 [b]	20	[73...109]	32 (91%)	3 (9%)	91	92	6	6.14
	B	35	32 [b]	20	[26...38]	32 (91%)	3 (9%)	32	32	1	4.29
STA CEPHASCREEN	A	21	53 [b]	20	[42...63]	21 (100%)	0 (0%)	53	53	2	3.73
	B	21	29 [b]	20	[23...34]	21 (100%)	0 (0%)	29	29	1	3.02
STA PTT Automate	A	20	69 [b]	20	[55...83]	20 (100%)	0 (0%)	69	70	3	3.83
	B	20	32 [b]	20	[25...38]	20 (100%)	0 (0%)	32	32	1	4.22
SynthASIL	A	42	52 [b]	20	[42...63]	41 (98%)	1 (2%)	52	53	4	7.33
	B	42	29 [b]	20	[23...34]	41 (98%)	1 (2%)	29	29	1	3.38
aPTT	A	34	84 [b]	20	[67...101]	33 (97%)	1 (3%)	84	85	4	4.50
	B	34	31 [b]	20	[25...38]	34 (100%)	0 (0%)	31	32	1	4.66

S-Curves of all samples



Youden-Plots of all sample pairs




Thrombinzeit sec


Split: Methode

Collective	Sample	AnzE	Target	%-Abw	limits	correct	outliers	MW	Median	SD	CV %
all	A	99	24 [b]	20	[19...29]	92 (93%)	7 (7%)	24	24	3	13.32
	B	98	19 [b]	20	[15...22]	95 (97%)	3 (3%)	19	19	2	8.32
IL	A	25	25 [b]	20	[20...30]	24 (96%)	1 (4%)	25	25	2	7.32
	B	25	19 [b]	20	[15...23]	24 (96%)	1 (4%)	19	19	2	8.05
Siemens andere	A	37	24 [b]	20	[19...29]	36 (97%)	1 (3%)	24	24	1	5.90
	B	37	19 [b]	20	[15...23]	37 (100%)	0 (0%)	19	19	1	5.40
Stago	A	21	20 [b]	20	[16...24]	21 (100%)	0 (0%)	20	20	1	3.59
	B	20	17 [b]	20	[14...21]	20 (100%)	0 (0%)	17	17	1	4.68
Thr < 1,0/BC- Thrombin	A	15	27 [b]	20	[22...33]	13 (87%)	2 (13%)	27	28	3	11.87
	B	15	19 [b]	20	[15...22]	13 (87%)	2 (13%)	19	19	2	8.28
Thr < 1,0/Thromboclotin	A	1	15 [b]*	20*	[12...18]*	1 (100%)*	0 (0%)*	15*	15*	-*	-*
	B	1	15 [b]*	20*	[12...18]*	1 (100%)*	0 (0%)*	15*	15*	-*	-*

S-Curves of all samples



Youden-Plots of all sample pairs





Fibrinogen mg/dl


Split: Reagens

Collective	Sample	AnzE	Target	%-Abw	limits	correct	outliers	MW	Median	SD	CV %
all	A	192	87 [b]	20	[69...104]	173 (90%)	19 (10%)	87	87	8	8.95
	B	192	260 [b]	20	[208...311]	187 (97%)	5 (3%)	260	260	19	7.28
IL	A	39	86 [b]	20	[68...103]	38 (97%)	1 (3%)	86	87	6	7.41
	B	39	250 [b]	20	[200...300]	38 (97%)	1 (3%)	250	248	18	7.27
Roche	A	31	82 [b]	20	[65...98]	31 (100%)	0 (0%)	82	82	7	8.51
	B	31	257 [b]	20	[205...308]	31 (100%)	0 (0%)	257	260	16	6.14
Siemens/D	A	62	86 [b]	20	[69...103]	59 (95%)	3 (5%)	86	85	8	8.95
	B	62	254 [b]	20	[204...305]	60 (97%)	2 (3%)	254	254	16	6.18
Siemens/DB	A	24	101 [b]	20	[81...121]	21 (88%)	3 (12%)	101	106	10	10.15
	B	24	271 [b]	20	[217...325]	22 (92%)	2 (8%)	271	264	23	8.55
Stago	A	35	87 [b]	20	[70...105]	34 (97%)	1 (3%)	87	88	4	4.83
	B	35	274 [b]	20	[219...329]	35 (100%)	0 (0%)	274	270	14	5.07
Technoclone	A	1	99 [b]*	20*	[79...119]*	1 (100%)*	0 (0%)*	99*	99*	-*	-*
	B	1	292 [b]*	20*	[234...350]*	1 (100%)*	0 (0%)*	292*	292*	-*	-*

S-Curves of all samples



Youden-Plots of all sample pairs




Fibrinogen derived mg/dl


Split: Methode

Collective	Sample	AnzE	Target	%-Abw	limits	correct	outliers	MW	Median	SD	CV %
all	A	4	148 [b]*	20*	[119...178]*	0 (0%)*	4 (100%)*	148*	153*	67*	44.89*
	B	4	193 [b]*	20*	[154...231]*	3 (75%)*	1 (25%)*	193*	190*	24*	12.29*
Innovin/recomb.	A	2	190 [b]*	20*	[152...228]*	2 (100%)*	0 (0%)*	190*	190*	0*	0.00*
	B	2	190 [b]*	20*	[152...228]*	2 (100%)*	0 (0%)*	190*	190*	0*	0.00*
RecombiPlasTin 2G/recomb.	A	1	98 [b]*	20*	[78...118]*	1 (100%)*	0 (0%)*	98*	98*	-*	-*
	B	1	286 [b]*	20*	[229...343]*	1 (100%)*	0 (0%)*	286*	286*	-*	-*
Thromborel S-Multi-Kal./human	A	1	115 [b]*	20*	[92...138]*	1 (100%)*	0 (0%)*	115*	115*	-*	-*
	B	1	185 [b]*	20*	[148...222]*	1 (100%)*	0 (0%)*	185*	185*	-*	-*

S-Curves of all samples



Youden-Plots of all sample pairs





Antithrombin III %


Split: Reagents

Collective	Sample	AnzE	Target	%-Abw	limits	correct	outliers	MW	Median	SD	CV %
all	A	150	29 [b]	35	[19...40]	145 (97%)	5 (3%)	29	30	4	12.00
	B	150	94 [b]	20	[75...113]	146 (97%)	4 (3%)	94	94	5	5.53
IL	A	30	26 [b]	35	[17...35]	29 (97%)	1 (3%)	26	26	4	15.09
	B	30	99 [b]	20	[79...119]	29 (97%)	1 (3%)	99	98	5	5.52
Roche	A	22	31 [b]	35	[20...42]	22 (100%)	0 (0%)	31	31	3	9.81
	B	22	93 [b]	20	[74...111]	22 (100%)	0 (0%)	93	93	4	4.42
Siemens	A	68	29 [b]	35	[19...40]	66 (97%)	2 (3%)	29	30	3	10.07
	B	68	93 [b]	20	[74...111]	66 (97%)	2 (3%)	93	93	5	5.00
Stago	A	29	31 [b]	35	[20...41]	29 (100%)	0 (0%)	31	30	3	8.93
	B	29	94 [b]	20	[76...113]	29 (100%)	0 (0%)	94	95	4	3.99
Technoclone	A	1	36 [b]*	35*	[23...49]*	1 (100%)*	0 (0%)*	36*	36*	.*	.*
	B	1	99 [b]*	20*	[79...119]*	1 (100%)*	0 (0%)*	99*	99*	.*	.*

S-Curves of all samples



Youden-Plots of all sample pairs




Factor II %


Split: Methode

Collective	Sample	AnzE	Target	%-Abw	limits	correct	outliers	MW	Median	SD	CV %
alle	A	17	32 [b]	30	[22...42]	17 (100%)	0 (0%)	32	32	2	6.31
	B	17	94 [b]	30	[66...122]	17 (100%)	0 (0%)	94	91	6	6.41

S-Curves of all samples



Youden-Plots of all sample pairs




Factor V %


Split: Methode

Collective	Sample	AnzE	Target	%-Abw	limits	correct	outliers	MW	Median	SD	CV %
alle	A	19	27 [b]	30	[19...35]	18 (95%)	1 (5%)	27	27	2	8.36
	B	19	94 [b]	30	[66...122]	18 (95%)	1 (5%)	94	95	6	6.31

S-Curves of all samples



Youden-Plots of all sample pairs




Factor VII %


Split: Methode

Collective	Sample	AnzE	Target	%-Abw	limits	correct	outliers	MW	Median	SD	CV %
alle	A	18	37 [b]	30	[26...48]	18 (100%)	0 (0%)	37	37	4	11.67
	B	18	94 [b]	30	[66...123]	18 (100%)	0 (0%)	94	94	11	11.46

S-Curves of all samples



Youden-Plots of all sample pairs




Factor X %


Split: Methode

Collective	Sample	AnzE	Target	%-Abw	limits	correct	outliers	MW	Median	SD	CV %
alle	A	18	32 [b]	30	[23...42]	18 (100%)	0 (0%)	32	33	3	9.63
	B	18	92 [b]	30	[65...120]	18 (100%)	0 (0%)	92	91	10	10.62

S-Curves of all samples



Youden-Plots of all sample pairs




Factor VIII %

Split: Methode

Collective	Sample	AnzE	Target	%-Abw	limits	correct	outliers	MW	Median	SD	CV %
alle	A	29	30 [b]	30	[21...39]	28 (97%)	1 (3%)	30	29	3	11.56
	B	29	94 [b]	30	[65...122]	29 (100%)	0 (0%)	94	94	7	7.76

S-Curves of all samples



Youden-Plots of all sample pairs




Factor IX %


Split: Methode

Collective	Sample	AnzE	Target	%-Abw	limits	correct	outliers	MW	Median	SD	CV %
alle	A	23	31 [b]	30	[22...41]	²³ (100%)	0 (0%)	31	31	3	11.21
	B	23	102 [b]	30	[72...133]	²³ (100%)	0 (0%)	102	101	11	10.42

S-Curves of all samples



Youden-Plots of all sample pairs




Factor XI %


Split: Methode

Collective	Sample	AnzE	Target	%-Abw	limits	correct	outliers	MW	Median	SD	CV %
alle	A	20	30 [b]	30	[21...39]	19 (95%)	1 (5%)	30	30	4	11.69
	B	20	96 [b]	30	[67...125]	20 (100%)	0 (0%)	96	96	12	12.60

S-Curves of all samples



Youden-Plots of all sample pairs




Factor XII %


Split: Methode

Collective	Sample	AnzE	Target	%-Abw	limits	correct	outliers	MW	Median	SD	CV %
alle	A	19	36 [b]	30	[25...46]	18 (95%)	1 (5%)	36	35	5	12.81
	B	19	102 [b]	30	[71...133]	19 (100%)	0 (0%)	102	102	11	10.63

S-Curves of all samples



Youden-Plots of all sample pairs




Factor XIII %


Split: Reagens

Collective	Sample	AnzE	Target	%-Abw	limits	correct	outliers	MW	Median	SD	CV %
all	A	26	28 [b]	30	[19...36]	25 (96%)	1 (4%)	28	27	3	11.18
	B	26	78 [b]	30	[55...102]	26 (100%)	0 (0%)	78	80	7	9.22
Berichrom/Siemens	A	9	28 [b]	30	[19...36]	9 (100%)	0 (0%)	28	27	2	8.68
	B	9	80 [b]	30	[56...104]	9 (100%)	0 (0%)	80	80	7	8.62
Hexamat/MBL	A	2	38 [b]*	30*	[26...49]*	2 (100%)*	0 (0%)*	38*	38*	10*	26.63*
	B	2	81 [b]*	30*	[57...105]*	2 (100%)*	0 (0%)*	81*	81*	9*	10.96*
Instr. Lab.	A	6	26 [b]	30	[18...34]	6 (100%)	0 (0%)	26	25	2	7.47
	B	6	72 [b]	30	[50...93]	6 (100%)	0 (0%)	72	71	3	3.83
Siemens/DB	A	8	28 [b]	30	[20...36]	8 (100%)	0 (0%)	28	28	3	10.84
	B	8	80 [b]	30	[56...104]	8 (100%)	0 (0%)	80	81	10	12.87
Technochrom/TC	A	1	34 [b]*	30*	[24...44]*	1 (100%)*	0 (0%)*	34*	34*	-*	-*
	B	1	80 [b]*	30*	[56...104]*	1 (100%)*	0 (0%)*	80*	80*	-*	-*

S-Curves of all samples



Youden-Plots of all sample pairs



Category (Collectives)

Thromboplastin time (quick) %

Number	Collective	Attribute	Specification
1	Cube-S/*****	Method	Cube-S/*****
2	Innovin-Multi-Kal./recomb.	Method	Innovin-Multi-Kal./recomb.
3	Innovin/recomb.	Method	Innovin/recomb.
4	Neoplastine	Method	Neopl.-Plus/rabbit Neoplastine CI +/-rabbit STA NEOPLASTIN CI +/-rabbit STA NEOPLASTIN R/recomb.
5	PT Rec/human	Method	PT Rec/human
6	PT Screen/human	Method	PT Screen/human
7	PT-Dimex jr./bovine+	Method	PT-Dimex jr./bovine+
8	ReadiPlasTin/recomb.	Method	ReadiPlasTin/recomb.
9	RecombiPlasTin 2G/recomb.	Method	RecombiPlasTin 2G/recomb.
10	STA HEPATO-PREST	Method	STA HEPATO-PREST / rabbit STA HEPATO-PREST-VB/rabbit
11	STA-NeoPTimal/rabbit	Method	STA PTF/rabbit STA-NeoPTimal/rabbit Technoplastin HIS/rabbit
12	Smart 700/*****	Method	Smart 700/*****
13	Smart 700/340/*****	Method	Smart 700/340/*****
14	Technoclot PT Owren	Method	Technoclot PT Owren autom./rabbit Technoclot PT Owren man.-KB/rabbit Technoclot PT Owren man.-P/rabbit
15	Thromborel S	Method	Thromborel S-Multi-Kal./human Thromborel S/human

INR

Number	Collective	Attribute	Specification
1	bovine	Method	Cube-S/***** PT-Dimex jr./bovine+ Smart 700/***** Smart 700/340/*****
2	human	Method	PT Rec/human PT Screen/human Thromborel S-Multi-Kal./human

			Thromborel S/human
3	rabbit	Method	Neopl.-Plus/rabbit Neoplastine CI +/-rabbit STA HEPATO-PREST / rabbit STA HEPATO-PREST-VB/rabbit STA NEOPLASTIN CI +/-rabbit STA PTF/rabbit STA-NeoPTimal/rabbit Technoclot PT Owren autom./rabbit Technoclot PT Owren man.-KB/rabbit Technoclot PT Owren man.-P/rabbit Technoplastin HIS/rabbit
4	recombinant	Method	Innovin-Multi-Kal./recomb. Innovin/recomb. ReadiPlasTin/recomb. RecombiPlasTin 2G/recomb. STA NEOPLASTIN R/recomb.

Partielle Thromboplastinzeit (aPTT) sec

Number	Collective	Attribute	Specification
1	Actin FS	Method	Actin FS
2	Actin andere	Method	Actin Actin FSL
3	Dapttin	Method	Dapttin
4	Pathromtin SL	Method	Pathromtin SL
5	STA CEPHASCREEN	Method	STA CEPHASCREEN
6	STA PTT Automate	Method	Cephalin LT CK PREST PTT Automate STA APTT (Ceph.-akt) STA CK PREST STA PTT Automate
7	SynthASIL	Method	aPTT SP SynthASIL
8	aPTT	Method	aPTT MedS aPTT Screen

Thrombinzeit sec

Number	Collective	Attribute	Specification
1	IL	Method	Thr < 2,0/Instr. Lab. Thr > 3,0/Instr. Lab.
2	Siemens andere	Method	Thr < 0,51/Test-Thr. Siemens Thr < 1,0/Test-Thr. Siemens Thr < 2,0/Test-Thr. Siemens Thr > 2,0/Test-Thr. Siemens
3	Stago	Method	Thr < 1,0/Stago Thr < 2,0/Stago

			Thr < 2,0/TC
4	Thr < 1,0/BC-Thrombin	Method	Thr < 1,0/BC-Thrombin
5	Thr < 1,0/Thromboclotin	Method	Thr < 1,0/Thromboclotin

Fibrinogen mg/dl

Number	Collective	Attribute	Specification
1	IL	Reagent	Instr. Lab./Elite Instr. Lab./TOP
2	Roche	Reagent	Roche Roche/BM
3	Siemens/D	Reagent	Siemens/D
4	Siemens/DB	Reagent	Siemens/DB
5	Stago	Reagent	Stago
6	Technoclone	Reagent	Technoclone

Fibrinogen derived mg/dl

Number	Collective	Attribute	Specification
1	Innovin/recomb.	Method	Innovin/recomb.
2	RecombiPlasTin 2G/recomb.	Method	RecombiPlasTin 2G/recomb.
3	Thromborel S-Multi-Kal./human	Method	Thromborel S-Multi-Kal./human

Antithrombin III %

Number	Collective	Attribute	Specification
1	IL	Reagent	Instr. Lab./TOP
2	Roche	Reagent	Roche Roche/BM
3	Siemens	Reagent	Berichrom/Siemens Innovance/Siemens Siemens/DB
4	Stago	Reagent	Stago
5	Technoclone	Reagent	Technoclone

Factor II %

Number	Collective	Attribute	Specification
1	alle	Method	Innovin/recomb. ReadiPlasTin/recomb. RecombiPlasTin 2G/recomb. STA NEOPLASTIN CI +/-rabbit STA NEOPLASTIN R/recomb. Technoplastin HIS/rabbit

			Thromborel S/human
--	--	--	--------------------

Factor V %

Number	Collective	Attribute	Specification
1	alle	Method	Innovin/recomb. ReadiPlasTin/recomb. RecombiPlasTin 2G/recomb. STA NEOPLASTIN CI +/-rabbit STA NEOPLASTIN R/recomb. Technoplastin HIS/rabbit Thromborel S/human

Factor VII %

Number	Collective	Attribute	Specification
1	alle	Method	Innovin/recomb. ReadiPlasTin/recomb. RecombiPlasTin 2G/recomb. STA NEOPLASTIN CI +/-rabbit STA NEOPLASTIN R/recomb. Technoplastin HIS/rabbit Thromborel S/human

Factor X %

Number	Collective	Attribute	Specification
1	alle	Method	Innovin/recomb. ReadiPlasTin/recomb. RecombiPlasTin 2G/recomb. STA NEOPLASTIN CI +/-rabbit STA NEOPLASTIN R/recomb. Technoplastin HIS/rabbit Thromborel S/human

Factor VIII %

Number	Collective	Attribute	Specification
1	alle	Method	Actin Actin FS Actin FSL Chrom./Siemens Chrom.Substr. Kaolin Pathromtin SL SIRON LS STA CK PREST SynthASIL

Factor IX %

Number	Collective	Attribute	Specification
1	alle	Method	Actin Actin FS Actin FSL Chrom.Substr. Pathromtin SL SIRON LS STA CK PREST SynthASIL

Factor XI %

Number	Collective	Attribute	Specification
1	alle	Method	Actin Actin FS Pathromtin SL SIRON LS STA CK PREST SynthASIL

Factor XII %

Number	Collective	Attribute	Specification
1	alle	Method	Actin Actin FS Pathromtin SL SIRON LS STA CEPHASCREEN STA CK PREST SynthASIL

Factor XIII %

Number	Collective	Attribute	Specification
1	Berichrom/Siemens	Reagent	Berichrom/Siemens
2	Hexamat/MBL	Reagent	Hexamat/MBL
3	Instr. Lab.	Reagent	Instr. Lab.
4	Siemens/DB	Reagent	Siemens/DB
5	Technochrom/TC	Reagent	Technochrom/TC

With best regards

Dr. Christoph Buchta, MBA
Technical Management

Prim. Univ. Doz. Dr. Alexander Haushofer
EQA Scheme Director